Mizuho raised the firm’s price target on Verastem (VSTM) to $15 from $14 and keeps an Outperform rating on the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VSTM:
- Is VSTM a Buy, Before Earnings?
- Verastem Reports Promising Phase 1/2a Trial Data
- Verastem announces encouraging data from ongoing phase 1/2a of VS-7375 dose
- Buy Rating Affirmed for Verastem’s VS-7375 Due to Promising Efficacy and Competitive Edge in KRAS G12D Inhibitors
- Verastem data ‘best-in-class’ despite slight decline, says RBC Capital